Overall Score

Scale Market Position

TBPH remains a mid-cap biotech with a market cap of about $0.88B and enterprise value of about $0.70B.

Revenue per share is $2.02, indicating a modest commercial base rather than dominant scale.

Pricing Power Margin Structure

Gross margin remains very strong at 90.8%, supporting evidence of product-level pricing power.

EBIT margin is 57.6% and net margin is 51.6%, but operating profit margin is still slightly negative at -2.9%, suggesting the moat is not yet fully reflected in operating discipline.

Switching Costs Customer Stickiness

Days of sales outstanding are 71.3 and the cash conversion cycle is 54.7 days, implying some customer stickiness but not a clearly entrenched lock-in effect.

No fresh news indicates a change in customer retention or switching behavior.

Intangible Assets Regulatory Barriers

High gross margins and a large R&D burden (24.6% of revenue) are consistent with a regulated, IP-driven biotech model.

No recent news suggests a new approval, patent event, or regulatory setback this month.

Cost Advantage Operating Efficiency

Operating returns remain weak, with return on invested capital at -0.6% and return on capital employed at -0.7%.

SG&A is still heavy at 49.6% of revenue, limiting evidence of a durable cost advantage.

Balance Sheet Resilience

Liquidity is strong, with a current ratio of 13.5 and cash per share of $7.50.

Net debt to EBITDA is negative at -2.88x, indicating a net cash position that supports moat durability.